Vaxart Reports Strong 2025 Financial Turnaround with $16.3M Net Income and Extended Cash Runway

summarizeSummary

Vaxart reported a significant financial improvement for full year 2025, achieving a net income of $16.3 million on substantially increased revenue, and extended its cash runway into Q2 2027 while advancing its vaccine pipeline.

check_boxKey Events

• Achieved Net Income in 2025

  Vaxart reported a net income of $16.3 million for the full year 2025, a significant improvement from a net loss of $66.9 million in 2024.

• Substantial Revenue Growth

  Revenue for the full year 2025 surged to $237.3 million, up from $28.7 million in 2024, primarily due to government contracts and the Dynavax collaboration.

• Extended Cash Runway

  The company ended 2025 with $63.8 million in cash, cash equivalents, and investments, providing a projected cash runway into the second quarter of 2027.

• COVID-19 Trial Progress

  Enrollment for the 5,400-participant Phase 2b COVID-19 trial is complete, with safety data from the sentinel cohort expected early Q2 2026 and topline data from all participants anticipated in Q4 2026.

auto_awesomeAnalysis

Vaxart's full year 2025 financial results demonstrate a significant turnaround, moving from a substantial net loss to profitability. The dramatic increase in revenue, primarily driven by government contracts and the Dynavax collaboration, coupled with an extended cash runway into Q2 2027, substantially de-risks the company's near-term operations. Progress in the pivotal Phase 2b COVID-19 trial and positive clinical data for the norovirus vaccine candidate further bolster the company's pipeline and strategic partnerships, indicating strong operational execution and potential for future growth.